Nautilus Biotechnology, Inc. Q3 FY2026 earnings call

• Strategic Focus on Proteoforms: Management emphasized that functional biology is driven by proteoforms (distinct protein forms defined by modifications, splicing, etc.) rather than just total protein quantity. The company's core thesis is "making functional biology measurable" through its Voyager platform, which uses iterative mapping to resolve single intact protein molecules at scale.
• Platform Validation and Data Quality: The Voyager platform demonstrated industry-leading reproducibility. The Tau assay achieved a median coefficient of variation (CV) of 5.5%. New oncology assays (AKT1, EGFR, P53) showed median CVs of 8.8%, 3.6%, and 6.6% respectively, significantly outperforming industry norms (~25%) and meeting the <10% target after only ~1 year of development compared to 5 years for Tau.
• Scientific Community Endorsement: The company received strong validation from key opinion leaders at HUPO World Congress. Partnerships include the ARPA-H funded SEEDS Consortium ($6M over 4 years) for Alzheimer’s and pediatric cancer research, and the Michael J. Fox Foundation for Parkinson’s disease alpha-synuclein assays. A seminal paper on Tau was published in Nature Methods.
• Commercial Execution and Team Building: Nautilus launched its Early Access program, securing initial customers like Baylor College of Medicine. A small but experienced sales team (3 people) has been hired to drive pipeline building for both neurodegeneration (Tau) and oncology targets.
• AI Integration Opportunity: Management highlighted that current AI models in biomedicine lack high-quality training data due to low reproducibility in existing proteomics methods. Nautilus aims to provide the high-fidelity, low-CV proteoform data required to train next-generation frontier AI models.

Nautilus Biotechnology operates as a single integrated segment focused on proteoform resolution technology. Total revenue for the third quarter of 2026 was $0.2 million, derived primarily from grant funding (specifically from the Michael J. Fox Foundation) and service revenue from the Early Access program. As the company is in an early commercial phase with no distinct product line segments generating separate reported revenues, individual segment financial performance and revenue contribution percentages are not applicable.

• Q4 2026 Revenue: Expected to grow sequentially from Q3, driven by year-end Early Access activity. Revenue will continue to be primarily from grants and services.
• Full Year 2026 Revenue: Upward revision; management now expects total 2026 revenue to exceed the prior outlook of approximately $0.5 million.
• Operating Expenses: Full-year operating expense growth is expected to remain in the single digits despite Q3 increases due to personnel and professional services costs.
• Cash Runway: Current cash position supports operations into Q1 2028.
• Capital Raise: The company is exploring fundraising options between now and mid-2027 to expand the assay portfolio, enhance platform capabilities, and build the commercial team.
• Product Launch Timeline:
  • Late 2026: AKT1 assay enters Early Access.
  • Early 2027: Commercial launch of Voyager platform; pre-orders open.
  • Mid-2027: First instrument shipments; General Availability (GA) of Tau, AKT1, and a second oncology assay kits.
  • Late 2027: Introduction of additional assay kits.
• Technical Milestones: Expectation to reduce sample input requirements by ~100-fold by mid-2027 to enable measurement of low-abundance proteins in biofluids like blood.

• Early Stage Commercialization: The company is in an early commercial phase; revenue is currently limited to grants and Early Access services, with significant revenue dependent on future instrument sales post-2027.
• Funding Uncertainty: Reliance on government grants (e.g., NIH S10) for academic instrument purchases introduces uncertainty regarding customer acquisition pace if grant cycles slow down.
• Execution Risk: Success depends on hitting aggressive timelines for assay development (20 assays by mid-2028), instrument shipping, and building a scalable commercial organization.
• Market Adoption: While interest is high, it remains to be seen if customers will transition from service-based models to purchasing expensive capital instruments immediately upon launch in 2027.
• Competitive Landscape: Although Nautilus claims unique capability, the broader proteomics field is evolving rapidly with traditional mass spectrometry and affinity-based assays continuing to improve.

Q: Subbu Nambi asked for details on the SEEDS program structure, revenue recognition timing, and the specific opportunity for AI dataset building given Nautilus' unique position. / A: Sujal Patel clarified that SEEDS is a four-year program with revenue recognized as work is completed, led by Buck Institute and Georgetown. Regarding AI, Patel noted that while AI success exists in antibody/small molecule design, the frontier opportunity lies in large cohort analysis where current data lacks agreement (high CV). Nautilus provides the necessary high-reliability, low-CV proteoform data to train these models, seeing this as a massive long-term driver despite being in early stages.

Q: Dan Brennan inquired about the qualitative state of the Early Access funnel, key milestones for the 2027 launch, and how the market readiness for such a novel product might impact the launch process. / A: CFO Anna Mowry confirmed confidence in sequential Q4 revenue growth without SEEDS contributions, though specific customer numbers were withheld. CEO Sujal Patel outlined two key 2027 milestones: finalizing pricing/specs for pre-orders and shipping beta units to prove reliability. He compared the launch strategy to disruptive platforms like 10x Genomics, expecting initial adoption via academic grants and pharma partnerships, with scaling accelerating in 2028 as more assays become available.

Q: Michael Sontag (on behalf of Puneet Sudha) asked about specific use cases observed in Early Access Tau work, changes in academic funding sentiment, and whether CapEx spending is material to the launch plan. / A: Co-founder Parag Mallick described three use case buckets: fundamental mechanistic biology (e.g., distinguishing tau forms in different model systems), disease biology (understanding selective vulnerability in Alzheimer's), and biomarker discovery (linking ApoE mutations to tau pathology). Patel noted academic funding sentiment is cautious but stable, with focus on helping customers secure S10 grants for 2028 placements. CFO Mowry stated that CapEx is not material to cash burn, with runway projections based on R&D and commercial team investments rather than facility/equipment costs.

Q: Max Masucci asked if SEEDS work includes biofluids like CSF or blood, what feedback from HUPO influenced launch priorities, and how much Tau alone vs. other assays would drive instrument utilization. / A: Parag Mallick confirmed SEEDS includes biofluid analysis (CSF/blood) for Tau and new EWS-FLI1 assays, plus platform optimization. He stated HUPO feedback validated the demand for increased content (more assays) and capabilities (sensitivity/sample type flexibility) via reagent kit changes. Patel added that Tau should not be viewed in isolation; concurrent GA availability of Tau, AKT1, and another oncology assay, plus a robust pipeline, is expected to keep instruments busy once they reach the ~$500k annual consumable pull-through threshold.